Baidu
map

BMJ:警惕!前列腺特异性α受体拮抗剂可增加男性跌倒及骨折的发生风险

2015-10-27 MedSci MedSci原创

BMJ:警惕!前列腺特异性α受体拮抗剂可增加男性跌倒及骨折的风险近日,来自加拿大韦仕敦大学的研究人员发现,前列腺特异性α受体拮抗剂可显著增加男性跌倒及骨折的发生风险,其原因或与前列腺特异性α受体拮抗剂可诱发机体低血压的发生有关。研究人员搜集了来自加拿大安大略省的147084名男性患者(年龄≥66岁)的数据。所有患者均在2003年六月至2013年11月期间接受了前列腺特异性α受体拮抗剂,阿夫唑嗪,或


图片来源:Pixabay

近日,来自加拿大韦仕敦大学的研究人员发现,前列腺特异性α受体拮抗剂可显著增加男性跌倒及骨折的发生风险,其原因或与前列腺特异性α受体拮抗剂可诱发机体低血压的发生有关。

研究人员搜集了来自加拿大安大略省的147084名男性患者(年龄≥66岁)的数据。所有患者均在2003年6月至2013年11月期间接受了前列腺特异性α受体拮抗剂,阿夫唑嗪,或西洛多辛治疗。此外研究人员还设置了对照组,1:1匹配(使用倾向评分模型)纳入了未接受前列腺特异性α受体拮抗剂的对照人群。评估的主要结果为,治疗后90天内暴露组与对照组人群因跌倒或骨折而就诊或住院的发生率;次要评估结果为低血压及头部外伤。

结果发现,与对照组人群相比,接受前列腺特异性α受体拮抗剂治疗的暴露组患者跌倒(OR:1.14, 95% CI:1.07-1.21,绝对风险增加了0.17%)及骨折(OR:1.16, 95% CI:1.04-1.29,绝对风险增加了0.06%)的发生危险显著升高。而在未接受前列腺特异性α受体拮抗剂治疗之前,患者跌倒及骨折的发生风险并未升高。此外,次要评估结果显示,接受前列腺特异性α受体拮抗剂治疗后患者低血压(OR:1.80)及头部外伤(OR:1.15)的发生率也显著高于对照人群。

此二组研究对象的98个变量(包括人口统计学因素,其他共存疾病,药物的使用,医疗保健的使用以及既往就诊情况等)相似。但是可能存在潜在的无法预测的混杂因素,包括身体不适,活动障碍及环境危险因素等。用于识别主要评估结果的数据其敏感性有限,故本研究结果的绝对风险值或被低估。此外,本研究仅纳入了66岁及以上的老年男性,84%的这些男性患者服用了坦索罗辛,所以本研究结果并不适用于年轻患者,而且不同药物所致风险的差异过小并无统计学意义。

原始出处:

Blayne Welk, Eric McArthur et al. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ, 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h5398 (Published 26 October 2015).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2016-01-27 doctording1

    不错,赞一个

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2016-01-27 doctording1

    实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2016-01-27 doctording1

    继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-11-16 gaoxiaoe
  6. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-29 Bobby7868

    真不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-28 梦想天空

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=60211, encodeId=391460211cc, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60212, encodeId=58476021257, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60213, encodeId=7dce6021307, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 00:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899077, encodeId=fb5f18990e7c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jun 09 07:16:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847734, encodeId=dc0d184e73429, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 16 02:16:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41858, encodeId=bc224185863, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Thu Oct 29 11:37:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511638, encodeId=f3951511638fe, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Oct 28 16:16:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41737, encodeId=3a7541e37ea, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 10:12:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41507, encodeId=e2bc4150eba, content=靠不靠谱? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Tue Oct 27 14:05:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 vpssa

    靠不靠谱?

    0

Baidu
map
Baidu
map
Baidu
map